The estimated Net Worth of Barry Ticho is at least 2.31 百万$ dollars as of 3 September 2024. Barry Ticho owns over 10,000 units of Stoke Therapeutics stock worth over 184,029$ and over the last 5 years he sold STOK stock worth over 1,387,188$. In addition, he makes 741,090$ as Chief Medical Officer at Stoke Therapeutics.
Sign up
Barry Ticho STOK stock SEC Form 4 insiders trading
Barry has made over 18 trades of the Stoke Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of STOK stock worth 6,000$ on 3 September 2024.
The largest trade he's ever made was exercising 174,027 units of Stoke Therapeutics stock on 1 June 2020 worth over 172,287$. On average, Barry trades about 15,317 units every 62 days since 2020. As of 3 September 2024 he still owns at least 12,485 units of Stoke Therapeutics stock.
You can see the complete history of Barry Ticho stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Barry Ticho biography
Dr. Barry S. Ticho M.D., Ph.D. serves as Chief Medical Officer of the Company. From February 2016 to September 2017, Dr. Ticho served as Head of Cardiovascular and Metabolic Diseases at Moderna, Inc., a biotechnology company. From October 2013 to February 2016, Dr. Ticho served as Head of External Research and Development Innovation for the Cardiovascular and Metabolic Disease Research Unit at Pfizer, Inc., a pharmaceutical company. Previously, Dr. Ticho served as the Vice President of Clinical Development at Biogen Inc., a biopharmaceutical company. Dr. Ticho holds a B.A. in Biology from Haverford College and an M.D. and a Ph.D. in Biochemistry and Molecular Biology from the University of Chicago.
What is the salary of Barry Ticho?
As the Chief Medical Officer of Stoke Therapeutics, the total compensation of Barry Ticho at Stoke Therapeutics is 741,090$. There are 4 executives at Stoke Therapeutics getting paid more, with Stephen Tulipano having the highest compensation of 1,176,400$.
How old is Barry Ticho?
Barry Ticho is 60, he's been the Chief Medical Officer of Stoke Therapeutics since 2017. There are 10 older and 9 younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics, Inc. is Dr. Edward M. Kaye M.D., Ph.D., 72, who is the CEO & Director.
What's Barry Ticho's mailing address?
Barry's mailing address filed with the SEC is C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD, MA, 01730.
Insiders trading at Stoke Therapeutics
Over the last 5 years, insiders at Stoke Therapeutics have traded over 49,612,288$ worth of Stoke Therapeutics stock and bought 4,288,550 units worth 94,976,062$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Investments, Lpwong Roderic...、Trust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of 1,639,987$. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth 6,000$.
What does Stoke Therapeutics do?
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
What does Stoke Therapeutics's logo look like?
Complete history of Barry Ticho stock trades at Stoke Therapeutics
Stoke Therapeutics executives and stock owners
Stoke Therapeutics executives and other stock owners filed with the SEC include:
-
Stephen Tulipano,
Chief Financial Officer -
Dr. Edward M. Kaye,
CEO & Director -
Dr. Edward M. Kaye M.D., Ph.D.,
CEO & Director -
Huw Nash,
Chief Operating Officer, Chief Business Officer -
Barry Ticho,
Chief Medical Officer -
Edward Kaye,
Chief Executive Officer, Director -
Dr. Barry S. Ticho FACC, M.D., Ph.D.,
Chief Medical Officer -
Stephen J. Tulipano CPA, CPA, MBA,
Chief Financial Officer -
Seth Harrison,
Independent Chairman of the Board -
Jennifer Burstein,
Independent Director -
Adrian Krainer,
Independent Director -
Arthur Tzianabos,
Independent Director -
Arthur Levin,
Independent Director -
Dr. Adrian R. Krainer Ph.D.,
Co-Founder, Independent Director & Member of Scientific Advisory Board -
Garry Menzel,
Independent Director -
Julie Smith,
Independent Director -
Gene Liau,
Executive Vice President, Head of Research and Preclinical Development -
Dawn Kalmar,
Chief Communications Officer -
Jonathan Allan J.D.,
Deputy Gen. Counsel -
Dr. Gene Liau,
Chief Scientific Officer -
Dr. Huw M. Nash Ph.D.,
COO & Chief Bus. Officer -
Nancy M. Wyant,
VP & Head of Clinical Operations -
Shamim Ruff,
Chief Regulatory Officer -
Joan Wood,
Head of HR -
Isabel Aznarez Ph.D.,
Co-Founder, VP & Head of Biology -
Group, Llc Green Jeremy Red...,
-
Samuel W. Hall,
Director -
Life Science Ventures, L.P....,
-
Investments, Lpwong Roderic...,
-
Robin A. Walker,
Chief Legal Officer, CCO & Sec -
Jonathan Allan,
GENERAL COUNSEL & CORP SEC -
Trust Blue Horizon Enterpri...,
-
Thomas Leggett,
Chief Financial Officer -
Ian F Smith,